Physician profile
Joyce R Philip
NPI 1235524406
$6,849.97
in general payments reported to CMS, 2019-2025
19 companies · $5,272 in 2025
The $5,272 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $191 · 2023: $595 · 2024: $791 · 2025: $5,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,925 · Food and Beverage: $2,655 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,925.00 |
| Food and Beverage | $2,654.75 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,119.79 | 2025 | |
| Genmab U.S., INC. | $657.55 | 2023-2025 | Epkinly |
| Janssen Biotech, INC. | $397.77 | 2022-2024 | Tecvayli, Darzalex |
| Abbvie INC. | $381.16 | 2023-2025 | |
| Genzyme Corporation | $191.48 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $125.50 | 2025 | Xpovio |
| Eisai INC. | $124.50 | 2025 | |
| Incyte Corporation | $109.98 | 2025 | Monjuvi |
| Adc Therapeutics America, INC. | $103.25 | 2025 | |
| Geron Corporation | $102.96 | 2025 | Rytelo |
| E.R. Squibb & Sons, L.L.C. | $90.28 | 2023 | Onureg |
| Tempus Ai, INC | $89.10 | 2024 | |
| Sumitomo Pharma America, INC. | $88.54 | 2023 | Orgovyx |
| Novocure INC. | $80.91 | 2024 | Optune |
| Bayer Healthcare Pharmaceuticals INC. | $78.07 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $70.90 | 2022 | |
| Boston Scientific Corporation | $19.19 | 2024 | |
| Kite Pharma, INC. | $19.04 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Philip listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.